‘Revolutionary’ US cannabis rescheduling set to increase companies’ profitability

The reclassification of cannabis to a less restrictive schedule of the US Controlled Substances Act will have crucial implications for the industry, especially as far as taxation is concerned, experts say.

News that the Drug Enforcement Administration (DEA) had agreed with the Department of Health and Human Services (HHS) to recommend moving cannabis from Schedule I to Schedule III of the act was leaked by US press at the end of April, paving the way for speculation over its economic impact for the sector.

Read full article
I'm already a subscriber

Tiziana Cauli

Senior reporter/health & science editor
Tiziana is an Italian journalist from Sardinia. She has worked for both international and local media in Italy, South Africa, France, Spain, the UK, Lebanon and Belgium. She also worked as a communications manager for several international NGOs in the humanitarian sector.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization